RxDoctor Payments Data

Arthur Gonzales, MD

General Practice · Schertz, TXNPI 1265613483

Payments from drug & device makers

$12,993in general payments, 2019–2025

Across 1,067 payments — averaging $12.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • Amgen$1K
  • Amarin Pharma, Inc.$857
  • Lilly USA, LLC$820
  • GSK$427
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$12,949100%
  • Education$440%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)315$3,278
Novo Nordisk235$1,906
Amgen75$1,190
Amarin Pharma, Inc.83$857
Lilly USA, LLC53$820
GSK28$427
Sanofi-aventis U.S. LLC19$423
Johnson & Johnson29$401
Pfizer25$292
Boehringer Ingelheim13$237
Abbott12$199
Supernus Pharmaceuticals, Inc.11$197
AstraZeneca7$195
Biohaven Pharmaceutical Holding Company Ltd.11$186
Zyla Life Sciences, Inc.20$184
Dexcom, Inc.9$173
Antares Pharma, Inc.14$166
Daiichi Sankyo Inc.9$150
Takeda Pharmaceuticals U.S.A., Inc.10$148
Avanir Pharmaceuticals, Inc.8$141
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$121
Merck7$110
Medtronic1$84
Novartis6$77
Bayer4$71
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$67
Corcept Therapeutics3$61
Astellas Pharma US Inc3$61
Esperion Therapeutics, Inc.4$60
Abiomed1$51
Upsher-smith Laboratories LLC3$49
Ironshore Pharmaceuticals Inc.3$48
Nevro Corp.2$42
Harmony Biosciences LLC2$37
Sumitomo Pharma America, Inc.2$36
Inspire Medical Systems, Inc.1$36
QOL Medical, LLC3$34
Jazz Pharmaceuticals Inc.2$33
Eisai Inc.2$30
Biohaven Pharmaceuticals, Inc.2$30
Ironwood Pharmaceuticals, Inc2$29
Exact Sciences1$25
Lexicon Pharmaceuticals, Inc.1$22
Neos Therapeutics, LP1$20
Phathom Pharmaceuticals, Inc.1$20
Ardelyx, Inc.1$16
Shire North American Group Inc1$15
Adlon Therapeutics L.p.1$15
Optinose US, Inc.1$15
Si-bone, Inc.1$15
Nestle Healthcare Nutrition Inc.1$15
Corium, LLC1$14
Scilex Pharmaceuticals Inc.1$14
Azurity Pharmaceuticals, Inc.1$13
Regeneron Healthcare Solutions, Inc.1$12
Clarus Therapeutics Inc.1$12
Althera Pharmaceuticals LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,993 in reported general payments places this provider in the 95th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas

Medicare billing

Part B allowed, 2024
$126,515
Medicare patients
272
Services billed
2,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide51$86,176
JardianceEmpagliflozin65$76,026
MounjaroTirzepatide41$62,557
OzempicSemaglutide41$62,550
TrulicityDulaglutide25$40,434
FarxigaDapagliflozin Propanediol24$29,296
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$26,328
EliquisApixaban18$22,413
VascepaIcosapent Ethyl33$20,317
TradjentaLinagliptin15$16,683
JanuviaSitagliptin Phosphate12$13,053
LinzessLinaclotide11$10,859
SymbicortBudesonide/Formoterol Fumarate16$6,903
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,868
Rosuvastatin Calcium317$4,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,906$148,72692 claims
Lilly USA, LLCMounjaro, Trulicity$820$102,99266 claims
Boehringer IngelheimJardiance, Tradjenta$237$92,70980 claims
AstraZenecaFarxiga, Symbicort$195$36,19940 claims
GSKTrelegy Ellipta$427$26,32824 claims
PfizerEliquis$292$22,41318 claims
MerckJanuvia$110$13,05312 claims
AbbVieLinzess, Synthroid$3,278$12,63931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,074 general practice providers in Texas.

Other general practice in Schertz

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →